Ferrochelatase cDNA delivered by adenoviral vector corrects biochemical defect in protoporphyric cells.
Protoporphyria is generally an autosomal dominant disease characterized genetically by mutations in the ferrochelatase gene. The interaction between the wild-type and mutant ferrochelatase protein is unknown. The aim of this study was to evaluate the ability to correct the enzymatic and biochemical defects in cells from patients with protoporphyria, using a replication-defective human adenovirus for gene transfer. Overexpression of ferrochelatase was accomplished by construction of a vector in which expression of the wild-type ferrochelatase cDNA was driven by the constitutive cytomegalovirus (CMV) promoter, introduction and packaging of the cDNA into human adenovirus dl309, and transduction of normal and protoporphyric fibroblasts. Fibroblasts from controls and patients were infected with the ferrochelatase adenovirus or a control adenovirus and assayed for ferrochelatase activity and the accumulation of protoporphyrin upon challenge with the precursor delta-aminolevulinic acid (ALA). At a multiplicity of infection (moi) of 10, greater than 85% of both the wild-type and protoporphyric fibroblasts were infected. The recombinant adenovirus increased the ferrochelatase protein content and activity in the wild-type and protoporphyric fibroblasts with equal efficiency. Therefore, the presence of the mutant ferrochelatase protein did not inhibit the ferrochelatase activity expressed by the transgene.
Magness
S T
ST
Department of Medicine, University of North Carolina, Chapel Hill 27599-7080, USA.
Brenner
D A
DA
D000256:Adenoviridae / Q000737:chemistry / Q000235:genetics* / Q000472:pathogenicity; D000622:Aminolevulinic Acid / Q000378:metabolism; D002478:Cells, Cultured; D003587:Cytomegalovirus / Q000235:genetics; D018076:DNA, Complementary; D003905:Deuteroporphyrins / Q000378:metabolism; D005294:Ferrochelatase / Q000235:genetics* / Q000378:metabolism* / Q000494:pharmacology; D005347:Fibroblasts / Q000821:virology; D006367:HeLa Cells / Q000378:metabolism / Q000821:virology; D006801:Humans; D015151:Immunoblotting; D017121:Porphyria, Hepatoerythropoietic / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D011401:Promoter Regions, Genetic; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism / Q000494:pharmacology; D014162:Transfection; D001616:beta-Galactosidase / Q000235:genetics
D018076:DNA, Complementary; D003905:Deuteroporphyrins; D011994:Recombinant Proteins; C028839:deuteroporphyrin-IX; D000622:Aminolevulinic Acid; D001616:beta-Galactosidase; D005294:Ferrochelatase